Guess Who Likes Medco Health (MHS)?

Last night, on Mad Money Jim Cramer told viewers to take a serious look at Medco Health (NYSE: MHS). Medco Health does well when big drug companies come off patent and go generic. Cramer noted, in the next five years, an estimated $77 billion worth of drug sales are scheduled to come off patent.

And that will be a boon to Medco Health because it will save them money. Medco does a tremendous amount of drug buying and generic versions will lower Medco's costs and enlarge its profit margins.

Cramer also said Medco Health is a defensive play and should be OK to buy in this volatile market.

You May Also Be Interested In

• Deutsche sees a buying opportunity in this MedTech stock
• Marvell earnings preview: Is a beat-and-raise quarter possible?
• EV maker set for margin recovery as overseas sales, new models boost earnings